Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MRUS 
Merus BV (MRUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: MRUS (3-star) is a REGULAR-BUY. BUY since 25 days. Profits (-5.36%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 52.81% | Avg. Invested days 34 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.74B USD | Price to earnings Ratio - | 1Y Target Price 87.2 |
Price to earnings Ratio - | 1Y Target Price 87.2 | ||
Volume (30-day avg) 674532 | Beta 1.15 | 52 Weeks Range 37.77 - 61.61 | Updated Date 04/2/2025 |
52 Weeks Range 37.77 - 61.61 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -969.93% |
Management Effectiveness
Return on Assets (TTM) -27.47% | Return on Equity (TTM) -42.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2208867572 | Price to Sales(TTM) 75.72 |
Enterprise Value 2208867572 | Price to Sales(TTM) 75.72 | ||
Enterprise Value to Revenue 61.13 | Enterprise Value to EBITDA -4.91 | Shares Outstanding 69090496 | Shares Floating 59193259 |
Shares Outstanding 69090496 | Shares Floating 59193259 | ||
Percent Insiders 2.04 | Percent Institutions 106.36 |
Analyst Ratings
Rating 4.75 | Target Price 86.07 | Buy 4 | Strong Buy 12 |
Buy 4 | Strong Buy 12 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Merus BV
Company Overview
History and Background
Merus BV is a clinical-stage immuno-oncology company developing innovative full-length multi-specific antibodies, referred to as Biclonicsu00ae, for cancer therapy. Founded in 2003 in Utrecht, The Netherlands, Merus is focused on creating novel therapeutics that address unmet needs in cancer treatment. It went public in 2016.
Core Business Areas
- Biclonicsu00ae Platform: Merus' core technology platform, developing full-length human bispecific and trispecific antibodies.
- Clinical Development: Focuses on the clinical development of its antibody candidates for various cancer indications.
- Research and Discovery: Dedicated to the discovery of novel targets and antibody candidates for cancer therapy.
Leadership and Structure
The company is led by a board of directors and an executive management team with expertise in biotechnology, oncology, and drug development.
Top Products and Market Share
Key Offerings
- Zenocutuzumab (MCLA-128): A bispecific antibody targeting HER2 and HER3, currently in clinical development for NRG1 fusion-positive cancers. Market share data for NRG1 fusion cancers is still developing as treatment options are limited. Competitors include companies developing targeted therapies for specific oncogenic drivers.
- Petosemtamab (MCLA-158): An antibody targeting EGFR, currently in clinical development. Competitors include companies developing EGFR inhibitors. Market share is not currently available, as product is still in clinical development.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing rapid growth, driven by advancements in antibody engineering and a growing understanding of the role of the immune system in cancer. The bispecific antibody market is particularly dynamic, with numerous companies developing novel therapeutics.
Positioning
Merus is positioned as a leader in the development of full-length bispecific antibodies for cancer therapy, leveraging its Biclonicsu00ae platform to create novel therapeutics. They have a focused pipeline targeting niche indications with high unmet need.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is very large and growing, projected to reach hundreds of billions of dollars. Merus is targeting specific subsets of patients with defined oncogenic drivers, representing a more focused TAM, but significant potential revenue opportunity. Exact market value is difficult to ascertain.
Upturn SWOT Analysis
Strengths
- Proprietary Biclonicsu00ae platform
- Strong intellectual property position
- Experienced management team
- Focused pipeline targeting specific patient populations
- Clinical data showing promising efficacy
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Reliance on clinical trial success
- Concentration of pipeline on specific targets
Opportunities
- Expansion of pipeline to additional targets and indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approval
- Advancements in cancer diagnostics enabling more precise patient selection
Threats
- Clinical trial failures
- Competition from other immuno-oncology companies
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- REGN
- XOMA
Competitive Landscape
Merus has a competitive advantage with its Biclonicsu00ae platform, which allows them to create novel multi-specific antibodies. However, they face significant competition from larger pharmaceutical companies with more resources and established market presence.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is driven by clinical trial advancement of key drug candidates, and company collaborations.
Future Projections: Future growth is dependent on clinical success, partnerships, and potential regulatory approvals. Analyst estimates are available from financial data providers.
Recent Initiatives: Focus on pivotal trials for Zenocutuzumab and Petosemtamab, pipeline expansion via early-stage research.
Summary
Merus BV is a promising immuno-oncology company with a novel technology platform and a focused pipeline. It needs to demonstrate clinical trial success to validate its approach and secure regulatory approvals. The company's success depends on the continued development of its leading product candidates as well as future partnerships. Competition will intensify as the bispecific market matures. The company has an experienced team but needs to continue growing a product revenue base.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
XOMA
XOMA Corp
XOMA
XOMA Corp
Sources and Disclaimers
Data Sources:
- Merus BV Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Merus BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-05-19 | CEO, President & Executive Director Dr. Sven Ante Lundberg M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 260 | Website https://www.merus.nl |
Full time employees 260 | Website https://www.merus.nl | ||
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.